Microorganisms. 2026 Jun 11. pii: 1306. [Epub ahead of print]14(6):
The global probiotic market is expanding rapidly, driven by growing demand for accessible strategies to support gut health, preventive care, and microbiome-based interventions. However, this commercial growth contrasts with the limited number of clinically validated, mechanism-driven products, highlighting a persistent gap between market expansion, scientific evidence, and therapeutic translation. Most current probiotics remain dominated by conventional genera, including Lactobacillus, Bifidobacterium, Bacillus, Saccharomyces, and Streptococcus, whereas live biotherapeutic products (LBPs) remain scarce. Synthetic biology is beginning to address this gap by transforming probiotics from empirically selected strains into programmable microbial platforms that sense disease-associated signals and produce defined therapeutic outputs. Escherichia coli Nissle 1917 (EcN) offers a valuable model chassis for engineered probiotics because of its long history of human use, safety record, genetic tractability, transient gut colonization, and scalable cultivation. As a rare Gram-negative probiotic, EcN naturally produces outer membrane vesicles that support host interaction, immunomodulation, and therapeutic cargo delivery. This review links probiotic market expansion with live biotherapeutic development and uses EcN to discuss emerging engineering strategies, therapeutic opportunities, and remaining translational barriers.
Keywords: EcN; engineering strategies; live biotherapeutic products; probiotic market; synthetic biology